Published in Cancer Weekly, May 5th, 2009
These pre-clinical studies include two ArQule compounds in clinical development: ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, and ARQ 621, a novel inhibitor of the Eg5 kinesin motor protein.
Summaries of these studies are presented below. Summaries of ArQule presentations at AACR ARQ 197 / c-Met Inhibition 1. Combination studies of tyrosine kinase inhibitors (TKIs): Assessment of potential cytotoxic synergy of ARQ 197 with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.